Trials / Completed
CompletedNCT06505265
A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants
An Open-Label, Skin and Plasma Pharmacokinetic Study of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to measure the effect of multiple doses of orally administered povorcitinib on skin PK and to characterize plasma PK parameters of povorcitinib following multiple doses of orally administered povorcitinib.in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Povorcitinib | Oral; Tablet |
Timeline
- Start date
- 2024-08-12
- Primary completion
- 2024-09-18
- Completion
- 2024-09-18
- First posted
- 2024-07-17
- Last updated
- 2024-09-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06505265. Inclusion in this directory is not an endorsement.